Fairmont Banff Springs Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2012


Here are the related meetings in 2018:
GPCR Structure and Function: Taking GPCR Drug Development and Discovery to the Next Level (B8)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

G Protein-Coupled Receptors: Molecular Mechanisms and Novel Functional Insights (B4)


Organizer(s) Arthur Christopoulos and Michel Bouvier
February 17—22, 2012
Fairmont Banff Springs • Banff, Alberta Canada
Abstract Deadline: Oct 17, 2011
Late Abstract Deadline: Nov 18, 2011
Scholarship Deadline: Oct 17, 2011
Early Registration Deadline: Dec 19, 2011

Sponsored by Bayer USA Foundation, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Merck & Co., Inc. and Vertex Pharmaceuticals Incorporated

Summary of Meeting:
The seven transmembrane-spanning G protein-coupled receptors (GPCRs) are the largest superfamily of receptors in the human genome, are involved in virtually all physiological processes and represent the targets for at least 30% of all current medicines. Recent years have witnessed the coalescing of a number of important paradigms, including ligand-biased signaling, allosteric modulation and receptor dimerization, with substantial advances in structural determination, chemical biology and in vivo approaches to studying GPCR function. These developments will undoubtedly have a profound impact on future approaches to GPCR-based drug discovery. This meeting will focus on the interplay between these developments, and how they can be exploited to advance the translational application of cutting-edge GPCR-based research.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


FRIDAY, FEBRUARY 17

15:00—19:30
Registration

Van Horne Foyer
18:15—19:15
Refreshments

Van Horne Foyer
19:15—20:30
Welcome and Keynote Address
Meeting has ended...abstracts no longer viewable online.

Van Horne Ballroom C
* Arthur Christopoulos, Monash University, Australia

Marc G. Caron, Duke University Medical Center, USA
Integrated Approaches to Understanding Drug Action at GPCRs


SATURDAY, FEBRUARY 18

07:00—08:00
Breakfast

Van Horne Ballroom A-B
08:00—11:15
GPCR Signaling I
Meeting has ended...abstracts no longer viewable online.

Van Horne Ballroom C
* Stephen J. Hill, University of Nottingham, UK

Jennifer L. Whistler, University of California, San Francisco, USA
Opioid Receptor Trafficking in Physiology and Disease

Paul A. Insel, University of California, San Diego, USA
Identification of New GPCR Targets for Cardiac Fibrosis

Hugh Rosen, ActivX Biosciences, USA
Chemical and Biological Insights from Alternate Binding Mode Agonists of SIP1 Receptor

Evi Kostenis, University of Bonn, Germany
Label Free Technology Platforms to Studying Pleiotropic 7TM Receptor Signaling

Jonathan D. Violin, Trevena Inc., USA
Short Talk: A G Protein-Biased mu-opioid Receptor Ligand Elicits Potent Analgesia but Reduced Constipation and Respiratory Depression Compared to Morphine in Rodents

Senthikumar Rajagopal, Virginia Commonwealth University, USA
Short Talk: Activation of G Protein-Coupled Bile Acid Receptor, TGR5 Induces Muscle Relaxation via PKA- and Epac-Mediated Inhibition of RhoA/Rho Kinase Pathway

09:20—09:40
Coffee Break

Van Horne Foyer
11:15
On Own for Lunch and Recreation

11:15—13:00
Poster Setup

Van Horne Ballroom A-B
13:00—22:00
Poster Viewing

Van Horne Ballroom A-B
16:30—17:00
Coffee Available

Van Horne Foyer
17:00—19:00
GPCR Physiology I
Meeting has ended...abstracts no longer viewable online.

Van Horne Ballroom C
* Laura M. Bohn, The Scripps Research Institute, USA

Michel Bouvier, University of Montreal, Canada
Targeting G Protein-Coupled Receptor Folding and Their Export from Endoplasmic Reticulum for Drug Discovery

Brigitte L. Kieffer, Douglas Institute, Canada
Delta Opioid Receptor Imaging in vivo: Anatomy, Dynamics and Physiology

Stefano Marullo, Institut Cochin, France
The beta2 Adrenergic Receptor as a Bacterial Entry Receptor

David Maussang-Detaille, Leiden/Amsterdam Center for Drug Research, VU University Amsterdam, Netherlands
Short Talk: Therapeutic Inhibition of Chemokine Receptors Using Nanobodies (VHH-Based Single Variable Domains)

19:00—20:00
Social Hour with Lite Bites

Van Horne Ballroom B-C
19:30—22:00
Poster Session 1

Van Horne Ballroom A-B

SUNDAY, FEBRUARY 19

07:00—08:00
Breakfast

Van Horne Ballroom A-B
07:30—08:00
Poster Setup

Van Horne BallroomA-B
08:00—17:00
Poster Viewing

Van Horne Ballroom A-B
08:00—11:15
Allosteric Modulation of GPCRs
Meeting has ended...abstracts no longer viewable online.

Van Horne Ballroom C
* Patrick M. Sexton, Monash University, Australia

Arthur Christopoulos, Monash University, Australia
Allosteric Modulation of GPCRs: From Function to Structure

Jean-Philippe Pin, Montpellier University, France
Structural Dynamics of Metabotropic Glutamate Receptors

Craig W. Lindsley, Vanderbilt University, USA
Discovery of Small Molecule Modulators of Family A and C GPCRs

Christian C. Felder, Eli Lilly and Company, USA
Challenges and Opportunities in Translating Allosteric Modulator-Based Drug Discovery

Kenneth E. Carlson, Ironwood Pharmaceuticals, USA
Short Talk: Direct Interaction between an Allosteric Agonist Pepducin and the Chemokine Receptor CXCR4

Amy Grunbeck, Rockefeller University, USA
Short Talk: Identification of a Small Molecule-Ligand-Binding Pocket in a G Protein-Coupled Receptor Using Genetically-Encoded Photocrosslinkers

09:20—09:40
Coffee Break

Van Horne Foyer
11:15—12:00
Lunch

12:00—14:30
Poster Session 2

Van Horne Ballroom A-B
16:30—17:00
Coffee Available

Van Horne Foyer
17:00—19:00
GPCR Signaling II
Meeting has ended...abstracts no longer viewable online.

Van Horne Ballroom C
* Michel Bouvier, University of Montreal, Canada

Stephane A. Laporte, McGill University, Canada
Biased Modulation of the Prostaglandin FP Receptor

Roger K. Sunahara, University of California, San Diego, USA
Crystal Structure of the beta2-Adrenergic Receptor in Complex with Gs: Elucidation of the Mechanism for Receptor-Mediated Nucleotide Exchange on Heterotrimeric G Proteins

JoAnn Trejo, University of California, San Diego, USA
Regulation of GPCR Signaling by Ubiquitination

Martin Beaulieu, Universite Laval, Canada
Short Talk: Quantitative Characterization of RTK-GPCR Transactivation Using Spatial Intensity Distribution Analysis (SpIDA)

19:00
On Own for Dinner


MONDAY, FEBRUARY 20

07:00—08:00
Breakfast

Van Horne Ballroom A-B
08:00—11:15
GPCR Physiology II
Meeting has ended...abstracts no longer viewable online.

Van Horne Ballroom C
* Brigitte L. Kieffer, Douglas Institute, Canada

Laura M. Bohn, The Scripps Research Institute, USA
Animal Model Correlates of GPCR Functional Selectivity: Studies of the Serotonin 2A Receptor

Ilpo Huhtaniemi, Imperial College London, UK
In vivo Demonstration of the Role of Dimerization for LH Receptor

Bernhard Bettler, University of Basel, Switzerland
Beyond GABA-B Receptor Heteromers: Insights into the Role of Auxiliary Subunits

Andrew B. Tobin, University of Glasgow, Scotland
Dissecting the in vivo Roles of GPCR Phosphorylation

Greg Polites, Sanofi-Aventis, USA
Short Talk: The CreLuc Reporter Mouse Model: A Transgenic Bioimaging Mouse Model that can Assay Ligand Activation of GPCRs

Ralf Jockers, Institute Cochin, France
Short Talk: Rare MTNR1B Variants Impairing Melatonin MT2 Receptor Function Strongly Contribute to Type 2 Diabetes

09:20—09:40
Coffee Break

Van Horne Foyer
11:15
On Own for Lunch and Recreation

Van Horne A-B
11:15—13:00
Poster Setup

Van Horne Ballroom A-B
13:00—22:00
Poster Viewing

Van Horne Ballroom A-B
16:30—17:00
Coffee Available

Van Horne Foyer
17:00—19:00
Structural and Computational Studies of GPCRs
Meeting has ended...abstracts no longer viewable online.

Van Horne Ballroom C
* Fiona H. Marshall, Heptares Therapeutics Ltd., UK

Brian K. Kobilka, Stanford University School of Medicine, USA
Structural Insights into the Dynamic Process of G Protein Coupled Receptor Activation

Patrick M. Sexton, Monash University, Australia
Polar Residues of the Transmembrane Domain of the Glucagon-like Peptide 1 Receptor Control Ligand-Directed Biased Signaling

Tara Mirzadegan, Janssen R&D Pharmaceutical Companies of Johnson & Johnson, USA
Bioinformatic Studies of GPCRs: From Sequence to Structure

Nevin A. Lambert, Medical College of Georgia, USA
Short Talk: Transient Self-Association of beta2 Adrenergic and CXCR4 Receptors

19:00—20:00
Social Hour with Lite Bites

Van Horne Ballroom A-B
19:30—22:00
Poster Session 3

Van Horne Ballroom A-B

TUESDAY, FEBRUARY 21

07:00—08:00
Breakfast

Van Horne Ballroom A-B
08:00—11:00
Changing Paradigms for GPCR Drug Discovery
Meeting has ended...abstracts no longer viewable online.

Van Horne Ballroom C
* Christian C. Felder, Eli Lilly and Company, USA

Marcel Hibert, University of Strasbourg, France
Novel FRET-Based Approaches to GPCR Drug Screening and more

Stephen Rees, AstraZeneca, UK
Drug Discovery Challenges for Orphan GPCRs

Fiona H. Marshall, Heptares Therapeutics Ltd., UK
Structure Based Drug Discovery for GPCRs

Stephen J. Hill, University of Nottingham, UK
New Insights into GPCR Pharmacology Using Fluorescent Ligands

Ron O. Dror, Stanford University, USA
Short Talk: Revealing the Atomic-Level Mechanisms of GPCR Activation and Drug Binding through Long-Timescale Simulation

09:20—09:40
Coffee Break

Van Horne Foyer
11:00
On Own for Lunch and Recreation

16:30—17:00
Coffee Available

Van Horne Foyer
17:00—19:00
New Topics in GPCR Structure and Function
Meeting has ended...abstracts no longer viewable online.

Van Horne Ballroom C
* Andrew B. Tobin, University of Glasgow, Scotland

Martin J. Lohse, Max Delbrück Center for Molecular Medicine, Germany
Single Molecule Studies of GPCRs

Ruben Abagyan, University of California, San Diego, USA
From a Few X-Ray Structures of GPCRs to Predictive Models of Many in Different States: Opportunities and Limitations

J. Silvio Gutkind, University of California, San Diego, USA
Novel GPCR-Regulated Oncogenic and Pro-Metastatic Signaling Circuitries

Sophie Roizard, Ecole Polytechnique Fédérale de Lausanne, Switzerland
Short Talk: Single Molecule Studies of Adenosine Receptors Compartmentation in Supported-Native Membranes by Correlated Electron and Fluorescence Microscopies

19:00—20:00
Social Hour with Lite Bites

Cascade
20:00—23:00
Entertainment

Cascade

WEDNESDAY, FEBRUARY 22

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



Keystone Symposia thanks our Sponsors for generously supporting this meeting:

Bayer USA Foundation Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Merck & Co., Inc. Vertex Pharmaceuticals Incorporated

We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13DA032154-01

The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



AstraZeneca


Eli Lilly and Company


Heptares Therapeutics Ltd


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676